 |
|
|
|
|
Novacea is actively evaluating new opportunities to license, co-develop or acquire additional clinical and IND-ready development candidates that complement our existing portfolio. Our disciplined approach to evaluating new opportunities focuses on identifying novel agents and innovative therapeutic modalities that can significantly advance the care of cancer patients. Specifically, this includes small molecule, protein and MAb approaches with one of the following profiles:
- Targeted therapies with a well-characterized mechanism of action
- Chemotherapeutic agents with novel activity
- Agents that "synergize" with established treatments
Benefits of a partnership
Each new development program will benefit from our strong ties to the oncology community and our integrated vision for streamlining the clinical site-to-submission process. This vision is borne from our management team's significant contributions to multiple product approvals and broadly encompasses development excellence in six key areas:
- Clinical, regulatory and product development strategy and trial design
- Site management and operations
- Data management and analysis
- Safety and pharmacovigilance
- Reporting, filing and submissions
- Market strategy, analysis and commercialization
Importantly, our knowledge and expertise in these and other key areas is supported internally by established systems and mature processes. This differentiating feature of our business model helps ensure that each new development program fully realizes the benefits of our experience, creativity and commitment to excellence.
New partnerships
To request additional information about our licensing interests and/or capabilities, or to discuss new partnership possibilities, please contact us.
|
|
|
|
|
|
|
